ストックスクリーナーアプリを入手
1.9091
1.09%
0.0206
前日終値:
$1.8885
開ける：
$1.9
24時間の取引高:
8,166
Relative Volume:
1.15
時価総額：
$10.83M
収益：
$2.35M
当期純損益:
$-2.56M
株価収益率:
-4.3428
EPS:
-0.4396
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-1.08%
1か月 パフォーマンス:
-2.60%
6か月 パフォーマンス:
-18.09%
1年 パフォーマンス:
+0.71%
1日の値動き範囲:
$1.82
$1.96
1週間の範囲:
$1.80
$2.00
52週間の値動き範囲:
$1.59
$5.96
Immuron Limited Adr Stock (IMRN) Company Profile
IMRN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| IMRN | 1.9091 | 10.83M | 2.35M | -2.56M | 0 | -0.4396 |
| VRTX | 449.19 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.15 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 599.00 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.91 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.97 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Immuron Limited Adr (IMRN) 最新ニュース
Immuron to Present at Q4 Virtual Investor Summit: Gut Disease Pipeline Showcase | IMRN Stock News - StockTitan
Immuron Travelan® continued strong sales growth - Quantisnow
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study - The Manila Times
IMRNImmuron Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Immuron Plans Phase 2 Trial for IMM-529 following FDA review - Markets Insider
Immuron Plans Phase 2 Trial for IMM-529 following FDA review | Daily Guardian - Daily Guardian Canada
Immuron secures new US DoD research award - Investing.com
Immuron secures new US DoD research award By Investing.com - Investing.com Australia
Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan® - GlobeNewswire Inc.
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now - GlobeNewswire Inc.
Treasuries slip, dollar firm as markets grapple with US politics By Reuters - Investing.com
Curtiss Wright CEO Lynn M Bamford buys $10.2k in stock By Investing.com - Investing.com India
Immuron CEO to present at Sharewise investor event By Investing.com - Investing.com
Immuron to raise up to $2M as part of an ATM equity offering (NASDAQ:IMRN) - Seeking Alpha
Immuron secures around US$2 million in funding after lodging Form F-3 and ATM prospectus with US SEC By ... - Investing.com
Immuron requests pre-IND meeting for IMM-529 with FDA filing - Markets Insider
Immuron requests pre-IND meeting for IMM-529 with FDA filing | Daily Guardian - Daily Guardian Canada
Immuron files pre-investigational new drug US FDA application for superbug fighting IMM-529 - Proactive Investors Australia
Immuron Surges On U.S. DoD Funding For Travelan Research - Yahoo Movies UK
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.34% - MSN
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Markets Insider
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.34% - Investing.com India
Immuron stock surges after mid-stage data for Travelan - Seeking Alpha
Check Up: These 4 ASX healthcare stocks come with Strong Buy recommendations - Stockhead
Check Up: Immuron wins big in US and Europe on travellers’ diarrhoea drug - Stockhead
Check Up: As Alzheimer’s grabs the spotlight, these ASX biotech stocks also impressed - Stockhead
45 Stocks Moving in Tuesday's Pre-Market SessionArbutus Biopharma (NASDAQ:ABUS), ACADIA Pharmaceutical - Benzinga
36 Stocks Moving in Monday's Pre-Market Session - Benzinga
The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortf - Benzinga
58 Biggest Movers From YesterdayArbutus Biopharma (NASDAQ:ABUS), Acer Therapeutics Inc (OTC:ACER) - Benzinga
IMMURON LIMITED - ShareCafe
Immuron Limited Trade Ideas — NASDAQ:IMRN - TradingView
29 Stocks Moving In Wednesday's Mid-Day SessionBabcock & Wilcox (NYSE:BW), AstroNova (NASDAQ:ALOT) - Benzinga
35 Stocks Moving In Tuesday's Mid-Day SessionAyala Pharmaceuticals (OTC:ADXS) - Benzinga
Immuron Limited Issues Correction to Misleading Halt Announcement Headline - GlobeNewswire
Pharma & Biotech - Proactive Investors USA
Immuron Limited Adr (IMRN) 財務データ
収益
当期純利益
現金流量
EPS
1.80%
0.42%
大文字化:
|
ボリューム (24 時間):